Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03313180




Registration number
NCT03313180
Ethics application status
Date submitted
13/10/2017
Date registered
18/10/2017
Date last updated
20/02/2024

Titles & IDs
Public title
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
Scientific title
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)
Secondary ID [1] 0 0
2016-003403-66
Secondary ID [2] 0 0
1199-0225
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Diseases, Interstitial 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Nintedanib

Experimental: Nintedanib - Patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) who took part in the parent trials 1199.214 (Nintedanib or Placebo) or 1199-0340 (Nintedanib). Patients continued in this trial and received Nintedanib 150 mg (milligram) twice daily (bid) unless they had reduced their dose to 100 mg bid trial medication (Nintedanib or Placebo) in the parent trial.

Patients receiving 100 mg bid trial medication at the end of the parent trial could receive either Nintedanib 100 mg bid or 150 mg bid at the discretion of the investigator.


Treatment: Drugs: Nintedanib
Administered twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Patients With Any Adverse Event (AE) Over the Course of the Trial
Timepoint [1] 0 0
First trial medication intake up to last trial drug intake, plus 7 days residual effect period, up to approximate 60 months.

Eligibility
Key inclusion criteria
* Patients who completed the parent trial 1199.214/1199-0340 per protocol and did not permanently discontinue study treatment
* Signed and dated written informed consent in accordance with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
* Women of childbearing potential must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly as well as one barrier method for 28 days prior to nintedanib treatment initiation, during the trial and for 3 months after last intake of nintedanib.
* Further inclusion criteria apply
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
* Bilirubin > 2 x ULN
* Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula.
* Clinically relevant anaemia at investigators discretion.
* Bleeding risk, any of the following

* Known genetic predisposition to bleeding according to the judgement of the investigator
* Patients who require

* Fibrinolysis, full-dose therapeutic anticoagulation
* High dose antiplatelet therapy.
* Hemorrhagic central nervous system (CNS) event after completion of the parent trial 1199.214/1199-0340
* Any of the following after last treatment of 1199.214/1199-0340:

* Haemoptysis or haematuria
* Active gastro-intestinal bleeding or Gastrointestinal (GI) - ulcers
* Gastric antral vascular ectasia (GAVE)
* Major injury or surgery
* Coagulation parameters: International normalised ratio (INR) >2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN at Visit 1.
* New major thrombo-embolic events developed after completion of the parent trial 1199.214/1199-0340:

* Stroke;
* Deep vein thrombosis;
* Pulmonary embolism;
* Myocardial infarction.
* Major surgery performed within the next 3 months
* Time period > 12 weeks between last drug intake in 1199.214 or > 1 week between last nintedanib intake in trial 1199-0340 and Visit 2 of this trial
* Usage of any investigational drug after completion of 1199.214/1199-0340 or planned usage of an investigational drug during the course of this trial.
* A disease or condition which may put the patient at risk because of participation in this trial (e.g. clinically relevant intestinal pseudoobstruction) or limit the patient's ability to participate in this trial
* Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial subject or unlikely to complete the trial
* Known hypersensitivity to the trial medication or its components (i.e. soya lecithin).
* Women who are pregnant, nursing, or who plan to become pregnant while in the trial
* Previous enrolment in this trial
* Further exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/11/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/01/2023
Sample size
Target
Accrual to date
Final
444
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Liverpool Hospital - Sydney
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
St Vincent's Hospital Melbourne - Fitzroy
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2170 - Sydney
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Utah
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad Autonoma Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Florida
Country [30] 0 0
Austria
State/province [30] 0 0
Innsbruck
Country [31] 0 0
Belgium
State/province [31] 0 0
Gent
Country [32] 0 0
Belgium
State/province [32] 0 0
Leuven
Country [33] 0 0
Belgium
State/province [33] 0 0
Liège
Country [34] 0 0
Brazil
State/province [34] 0 0
Curitiba
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Chile
State/province [36] 0 0
Concepción
Country [37] 0 0
Chile
State/province [37] 0 0
Talca
Country [38] 0 0
China
State/province [38] 0 0
Beijing
Country [39] 0 0
China
State/province [39] 0 0
Changchun
Country [40] 0 0
China
State/province [40] 0 0
Chengdu
Country [41] 0 0
China
State/province [41] 0 0
Hefei
Country [42] 0 0
China
State/province [42] 0 0
Shanghai
Country [43] 0 0
China
State/province [43] 0 0
Shenyang
Country [44] 0 0
Czechia
State/province [44] 0 0
Prague
Country [45] 0 0
Denmark
State/province [45] 0 0
Aarhus N
Country [46] 0 0
Denmark
State/province [46] 0 0
Odense
Country [47] 0 0
Finland
State/province [47] 0 0
Helsinki
Country [48] 0 0
Finland
State/province [48] 0 0
Turku
Country [49] 0 0
France
State/province [49] 0 0
Bobigny
Country [50] 0 0
France
State/province [50] 0 0
Bron
Country [51] 0 0
France
State/province [51] 0 0
Lille
Country [52] 0 0
France
State/province [52] 0 0
Montpellier
Country [53] 0 0
France
State/province [53] 0 0
Nantes
Country [54] 0 0
France
State/province [54] 0 0
Nice
Country [55] 0 0
France
State/province [55] 0 0
Paris
Country [56] 0 0
France
State/province [56] 0 0
Rennes
Country [57] 0 0
France
State/province [57] 0 0
Rouen
Country [58] 0 0
France
State/province [58] 0 0
Toulouse
Country [59] 0 0
France
State/province [59] 0 0
Tours
Country [60] 0 0
Germany
State/province [60] 0 0
Donaustauf
Country [61] 0 0
Germany
State/province [61] 0 0
Dresden
Country [62] 0 0
Germany
State/province [62] 0 0
Erlangen
Country [63] 0 0
Germany
State/province [63] 0 0
Greifswald
Country [64] 0 0
Germany
State/province [64] 0 0
Hamburg
Country [65] 0 0
Germany
State/province [65] 0 0
Hannover
Country [66] 0 0
Germany
State/province [66] 0 0
Heidelberg
Country [67] 0 0
Germany
State/province [67] 0 0
Kiel
Country [68] 0 0
Germany
State/province [68] 0 0
Münster
Country [69] 0 0
Germany
State/province [69] 0 0
Tübingen
Country [70] 0 0
Greece
State/province [70] 0 0
Athens
Country [71] 0 0
India
State/province [71] 0 0
Bangalore
Country [72] 0 0
India
State/province [72] 0 0
Chandigarh
Country [73] 0 0
India
State/province [73] 0 0
Delhi
Country [74] 0 0
India
State/province [74] 0 0
Hyderabad
Country [75] 0 0
India
State/province [75] 0 0
Jaipur
Country [76] 0 0
India
State/province [76] 0 0
Nagpur
Country [77] 0 0
India
State/province [77] 0 0
New Delhi
Country [78] 0 0
India
State/province [78] 0 0
Pune
Country [79] 0 0
Israel
State/province [79] 0 0
Haifa
Country [80] 0 0
Israel
State/province [80] 0 0
Petah Tiqwa
Country [81] 0 0
Israel
State/province [81] 0 0
Tel Aviv
Country [82] 0 0
Italy
State/province [82] 0 0
Genova
Country [83] 0 0
Italy
State/province [83] 0 0
Monza
Country [84] 0 0
Italy
State/province [84] 0 0
Napoli
Country [85] 0 0
Italy
State/province [85] 0 0
Padova
Country [86] 0 0
Italy
State/province [86] 0 0
Roma
Country [87] 0 0
Japan
State/province [87] 0 0
Aichi, Seto
Country [88] 0 0
Japan
State/province [88] 0 0
Fukuoka, Kurume
Country [89] 0 0
Japan
State/province [89] 0 0
Hokkaido, Sapporo
Country [90] 0 0
Japan
State/province [90] 0 0
Hyogo, Himeji
Country [91] 0 0
Japan
State/province [91] 0 0
Kanagawa, Kawasaki
Country [92] 0 0
Japan
State/province [92] 0 0
Kanagawa, Sagamihara
Country [93] 0 0
Japan
State/province [93] 0 0
Kanagawa, Yokohama
Country [94] 0 0
Japan
State/province [94] 0 0
Nagasaki, Nagasaki
Country [95] 0 0
Japan
State/province [95] 0 0
Osaka, Osakasayama
Country [96] 0 0
Japan
State/province [96] 0 0
Osaka, Sakai
Country [97] 0 0
Japan
State/province [97] 0 0
Osaka, Takatsuki
Country [98] 0 0
Japan
State/province [98] 0 0
Saitama, Iruma-gun
Country [99] 0 0
Japan
State/province [99] 0 0
Shizuoka, Hamamatsu
Country [100] 0 0
Japan
State/province [100] 0 0
Tokushima, Tokushima
Country [101] 0 0
Japan
State/province [101] 0 0
Tokyo, Bunkyo-Ku
Country [102] 0 0
Japan
State/province [102] 0 0
Tokyo, Ota-ku
Country [103] 0 0
Japan
State/province [103] 0 0
Tokyo, Shinjyuku-ku
Country [104] 0 0
Malaysia
State/province [104] 0 0
Georgetown Pulau Pinang
Country [105] 0 0
Malaysia
State/province [105] 0 0
Kuala Lumpur
Country [106] 0 0
Mexico
State/province [106] 0 0
Ciudad de México
Country [107] 0 0
Netherlands
State/province [107] 0 0
Amsterdam
Country [108] 0 0
Netherlands
State/province [108] 0 0
Leiden
Country [109] 0 0
Netherlands
State/province [109] 0 0
Nijmegen
Country [110] 0 0
Netherlands
State/province [110] 0 0
Rotterdam
Country [111] 0 0
Norway
State/province [111] 0 0
Oslo
Country [112] 0 0
Norway
State/province [112] 0 0
Tromsø
Country [113] 0 0
Poland
State/province [113] 0 0
Bydgoszcz
Country [114] 0 0
Poland
State/province [114] 0 0
Krakow
Country [115] 0 0
Poland
State/province [115] 0 0
Rzeszow
Country [116] 0 0
Poland
State/province [116] 0 0
Wroclaw
Country [117] 0 0
Portugal
State/province [117] 0 0
Almada
Country [118] 0 0
Portugal
State/province [118] 0 0
Amadora
Country [119] 0 0
Portugal
State/province [119] 0 0
Coimbra
Country [120] 0 0
Portugal
State/province [120] 0 0
Ponte de Lima
Country [121] 0 0
Portugal
State/province [121] 0 0
Porto
Country [122] 0 0
Portugal
State/province [122] 0 0
Vila Nova de Gaia
Country [123] 0 0
Spain
State/province [123] 0 0
Barcelona
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Valencia
Country [126] 0 0
Spain
State/province [126] 0 0
Vigo
Country [127] 0 0
Sweden
State/province [127] 0 0
Gothenburg
Country [128] 0 0
Switzerland
State/province [128] 0 0
Zürich
Country [129] 0 0
Thailand
State/province [129] 0 0
Bangkok
Country [130] 0 0
Thailand
State/province [130] 0 0
Muang
Country [131] 0 0
Thailand
State/province [131] 0 0
Songkhla
Country [132] 0 0
United Kingdom
State/province [132] 0 0
London
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main objective is to assess long term safety of treatment with oral nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
Trial website
https://clinicaltrials.gov/study/NCT03313180
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03313180